Emmaus Life Sciences, Inc. (EMMA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 15M 30M 45M Q3 '21: 23.8M Q4 '21: 20.6M Q1 '22: 18.5M Q2 '22: 16.3M Q3 '22: 15.5M Q4 '22: 18.4M Q1 '23: 21.9M Q2 '23: 28.4M Q3 '23: 28.5M Q4 '23: 29.6M Q1 '24: 25.4M Q2 '24: 20M Q3 '24: 20.4M Q4 '24: 16.7M Q1 '25: 16.6M Q2 '25: 14M Q3 '25: 11.9M Q4 '25: 12.5M Q1 '26: 12M Q2 '26: 15.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 10M 20M 30M Q3 '21: 21.7M Q4 '21: 17.3M Q1 '22: 14.6M Q2 '22: 12.5M Q3 '22: 11.5M Q4 '22: 15.8M Q1 '23: 19.9M Q2 '23: 26.3M Q3 '23: 26.7M Q4 '23: 28.3M Q1 '24: 24.2M Q2 '24: 19.1M Q3 '24: 19.3M Q4 '24: 15.5M Q1 '25: 15.4M Q2 '25: 12.9M Q3 '25: 11M Q4 '25: 11.6M Q1 '26: 11.2M Q2 '26: 14.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '21: -802K Q4 '21: -6.1M Q1 '22: -7.6M Q2 '22: -9.5M Q3 '22: -10.1M Q4 '22: -6.6M Q1 '23: -4.7M Q2 '23: 83K Q3 '23: 767K Q4 '23: 3.5M Q1 '24: 2M Q2 '24: -779K Q3 '24: 18K Q4 '24: -1.9M Q1 '25: -134K Q2 '25: -1.1M Q3 '25: -1.2M Q4 '25: 231K Q1 '26: 388K Q2 '26: 4.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-21M -14M -7M 0 7M 14M 21M Q3 '21: -9.4M Q4 '21: -15.9M Q1 '22: -9.1M Q2 '22: -20.4M Q3 '22: -17.7M Q4 '22: -10.6M Q1 '23: -12.5M Q2 '23: -5.2M Q3 '23: -4.7M Q4 '23: -3.7M Q1 '24: -4.6M Q2 '24: -5.3M Q3 '24: -3.5M Q4 '24: -6.5M Q1 '25: -4.4M Q2 '25: -3.4M Q3 '25: -7.3M Q4 '25: -7.5M Q1 '26: -8.5M Q2 '26: -6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 1.5M 3M 4.5M Q3 '21: 2.2M Q4 '21: 3.3M Q1 '22: 3.9M Q2 '22: 3.8M Q3 '22: 3.9M Q4 '22: 2.6M Q1 '23: 2M Q2 '23: 2.1M Q3 '23: 1.8M Q4 '23: 1.3M Q1 '24: 1.2M Q2 '24: 903K Q3 '24: 1.1M Q4 '24: 1.2M Q1 '25: 1.2M Q2 '25: 1.1M Q3 '25: 931K Q4 '25: 857K Q1 '26: 800K Q2 '26: 994K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-9M -6M -3M 0 3M 6M 9M Q4 '20: -2.5M Q1 '21: -8.3M Q2 '21: -4.5M Q3 '21: -208K Q4 '21: -1.3M Q1 '22: -2M Q2 '22: -3.3M Q3 '22: -5.9M Q4 '22: -5.1M Q1 '23: -1.6M Q2 '23: -1.9M Q3 '23: -862K Q4 '23: -1.5M Q1 '24: -71K Q2 '24: -1.7M Q3 '24: -1.6M Q4 '24: -2.3M Q1 '25: -2.1M Q2 '25: -2.1M Q3 '25: -1.9M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Free Cash Flow TTM

-9M -6M -3M 0 3M 6M 9M Q4 '18: -8.4M Q1 '19: -7.3M Q2 '19: -4.7M Q3 '19: -5.9M Q4 '19: -4.6M Q1 '20: -1.6M Q2 '20: -5M Q3 '20: -4.8M Q4 '20: -2.5M Q2 '22: -3.4M Q3 '22: -6M Q4 '22: -5.1M Q1 '23: -1.7M Q2 '23: -1.9M Q3 '23: -881K Q4 '23: -1.5M Q1 '24: -86K Q2 '24: -1.7M Q3 '24: -1.6M Q4 '24: -2.3M Q1 '19 Q4 '19 Q3 '20 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '20: 48.6M Q2 '20: 49M Q3 '20: 49M Q1 '21: 49.1M Q2 '21: 49.3M Q3 '21: 49.3M Q1 '22: 49.3M Q2 '22: 49.3M Q3 '22: 49.6M Q1 '23: 50.7M Q2 '23: 52.9M Q3 '23: 138.4M Q1 '24: 61.8M Q2 '24: 63.4M Q3 '24: 63.9M Q1 '25: 63.9M Q2 '25: 63.9M Q3 '25: 63.9M Q1 '26: 70.2M Q2 '26: 120.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 0.00 15.00 30.00 45.00 Q3 '20: 0.05 Q4 '20: 30.00 Q1 '21: 29.72 Q2 '21: 29.96 Q3 '21: 29.79 Q4 '21: -0.32 Q1 '22: -0.18 Q2 '22: -0.41 Q3 '22: -0.36 Q4 '22: -0.21 Q1 '23: -0.25 Q2 '23: -0.10 Q3 '24: -0.03 Q4 '24: -0.10 Q1 '25: -0.07 Q2 '25: -0.06 Q3 '25: -0.12 Q4 '25: -0.12 Q1 '26: -0.13 Q2 '26: -0.09 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.